SEC Form 4 · accession 0001140361-15-004118
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ely Benaim
Officer — Chief Medical Officer
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.71 | Feb 2, 2015 | A | 1,200,000 | A | — | Feb 2, 2025 | Common Stock | 1,200,000 | 1,200,000 | D |
Explanation of responses
- F1Options vest and become exercisable based upon the following schedule: 300,000 on February 2, 2016, and 25,000 on the first business day of each month beginning March 2016 and ending February 2019.